Framing Messages for Smoking Cessation With Bupropion - 6

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized study of message framing in individuals beginning a smoking cessation program utilizing bupropion SR and brief counseling, videos, and pamphlets.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Collaborator: National Institute on Drug Abuse (NIDA)
• Treatments: Bupropion

Criteria

Exclusion Criteria:

• Pregnant or nursing women, or women of child-bearing potential who are not using an adequate method of contraception

• Psychiatric illnesses requiring psychotropic medications (i.e., psychosis, major depression, mania), or the presence of suicidality or homocidality

• Current use of nicotine replacement therapies (i.e., nicotine patch, gum, or lozenges, nasal spray, or inhaler), bupropion (Zyban, Wellbutrin), or marijuana or current participation in another smoking cessation treatment

• Presence of unstable medical conditions (i.e., cardiac, hepatic, renal disease, diabetes mellitus) that would make a trial of bupropion SR hazardous

• Have taken monoamine oxidase inhibitors or metoprolol succinate within the past six weeks

• History of anorexia nervosa or bulimia

• Previous hypersensitivity to bupropion

• History of alcohol or other drug dependence in the past one year

• History of seizure disorder of any etiology (i.e., brain tumor, traumatic brain injury, substance-induced seizures, etc.)

• Any finding that in the view of the principal investigator would compromise the subject's ability to fulfill the protocol visit schedule and visit requirements or put the subject at risk

• Sharing home or work environment with current or past participant

• No couples or participants who see each other every day